Switching targeted therapies for advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have HER2-positive breast cancer that has spread to other parts of the body or is advanced.
- You have at least one tumor that can be measured on a scan like CT or MRI.
- You are generally able to care for yourself and are not bedridden more than half the day.
- You have not had a major surgery in the last 4 weeks, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.